The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Open accessAbstract
BACKGROUND: Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown. METHODS: We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia. RESULTS: The risk of overall clinical progression--defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk reduction, P=0.002), as compared with placebo. The reduction in risk associated with combination therapy (66 percent for the comparison with placebo, P<0.001) was significantly greater than that associated with doxazosin (P<0.001) or finasteride (P<0.001) alone. The risks of acute urinary retention and the need for invasive therapy were significantly reduced by combination therapy (P<0.001) and finasteride (P<0.001) but not by doxazosin. Doxazosin (P<0.001), finasteride (P=0.001), and combination therapy (P<0.001) each resulted in significant improvement in symptom scores, with combination therapy being superior to both doxazosin (P=0.006) and finasteride (P<0.001) alone. CONCLUSIONS: Long-term combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression of benign prostatic hyperplasia significantly more than did treatment with either drug alone. Combination therapy and finasteride alone reduced the long-term risk of acute urinary retention and the need for invasive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,845
The Influence of Finasteride on the Development of Prostate Cancer
Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., Lieber, M. M., Cespedes, R. D., Atkins, J. N., Lippman, S. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030660 · Cited by 2,518
Self-citationSathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O'leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & Measurement Committee of the American Urological Association (2017) · Journal of Urology · doi:10.1016/j.juro.2016.10.071 · Cited by 1,940
The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271701 · Cited by 1,124
Self-citationMcConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., Albertsen, P., Roehrborn, C. G., Nickel, J. C., Wang, D. Z., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802263380901 · Cited by 1,120
Self-citationThe Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350801 · Cited by 792
Self-citationRoehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Self-citationStatistical Considerations in the Intent-to-Treat Principle
Lachin, J. M. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00046-5 · Cited by 652
Wasson, J. H., Reda, D. J., Bruskewitz, R. C., Elinson, J., Keller, A. M., & Henderson, W. G. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501123320202 · Cited by 605
Barry, M. J., Williford, W. O., Chang, Y., Machi, M., Jones, K. M., Walker-Corkery, E., & Lepor, H. (1995) · Journal of Urology · doi:10.1016/s0022-5347(01)66780-6 · Cited by 510
Self-citationKirby, R. S., Roehrborn, C., Boyle, P., Bartsch, G., Jardin, A., Cary, M. M., Sweeney, M., & Grossman, E. B. (2003) · Urology · doi:10.1016/s0090-4295(02)02114-3 · Cited by 389
Self-citationRoehrborn, C. G., McConnell, J. D., Lieber, M., Kaplan, S., Geller, J., Malek, G. H., Castellanos, R., Coffield, S., Saltzman, B., Resnick, M., et al. (1999) · Urology · doi:10.1016/s0090-4295(98)00654-2 · Cited by 333
Self-citationProperties of the urn randomization in clinical trials
Wei, L. J., & Lachin, J. M. (1988) · Controlled Clinical Trials · doi:10.1016/0197-2456(88)90048-7 · Cited by 308
Biostatistical methods : the assessment of relative risks
Lachin, J. M. (2000) · Cited by 272
ROEHRBORN, C. G., McCONNELL, J., BONILLA, J., ROSENBLATT, S., HUDSON, P. B., MALEK, G. H., SCHELLHAMMER, P. F., BRUSKEWITZ, R., MATSUMOTO, A. M., HARRISON, L. H., et al. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67962-1 · Cited by 265
Self-citationWelch, G., Weinger, K., & Barry, M. J. (2002) · Urology · doi:10.1016/s0090-4295(01)01506-0 · Cited by 238
Nickel, J. C., Fradet, Y., Boake, R., Pommerville, P. J., Perreault, J., Afridi, S. K., & ELHILALI, M. M. (1996) · Europe PMC (PubMed Central) · Cited by 225
Roehrborn, C. G., Oesterling, J. E., Auerbach, S., Kaplan, S. A., Keith Lloyd, L., Milam, D. F., & Padley, R. J. (1996) · Urology · doi:10.1016/s0090-4295(99)80409-9 · Cited by 207
Self-citationBiostatistical Methods: The Assessment of Relative Risks
Lachin, J. M. (2000) · Wiley Series in Probability and Statistics · doi:10.1002/9780470317051 · Cited by 200
Marberger, M. J. (1998) · Urology · doi:10.1016/s0090-4295(98)00094-6 · Cited by 190
Roehrborn, C. G., Girman, C. J., Rhodes, T., Hanson, K. A., Collins, G. N., Sech, S. M., Jacobsen, S. J., Garraway, W. M., & Lieber, M. M. (1997) · Urology · doi:10.1016/s0090-4295(97)00031-9 · Cited by 166
Self-citationAndersen, J. T., Curtis Nickel, J., Marshall, V. R., Schulman, C. C., & Boyle, P. (1997) · Urology · doi:10.1016/s0090-4295(97)00185-4 · Cited by 161
Goodness-of-Fit Analysis for the Cox Regression Model Based on a Class of Parameter Estimators
Lin, D. Y. (1991) · Journal of the American Statistical Association · doi:10.1080/01621459.1991.10475101 · Cited by 136
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial
Bautista, O. M., Kusek, J. W., Nyberg, L. M., McConnell, J. D., Bain, R. P., Miller, G. J., Crawford, E. D., Kaplan, S. A., Sihelnik, S. A., Brawer, M. K., et al. (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00263-5 · Cited by 104
Self-citationLachin, J. M. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110903 · Cited by 100
The Pathophysiology of Benign Prostatic Hyperplasia
McConnell, J. D. (1991) · Journal of Andrology · doi:10.1002/j.1939-4640.1991.tb00272.x · Cited by 95
Self-citationExplained Residual Variation, Explained Risk, and Goodness of Fit
Korn, E. L., & Simon, R. M. (1991) · The American Statistician · doi:10.1080/00031305.1991.10475802 · Cited by 84
Indications for treatment of benign prostatic hyperplasia. The American Urological Association Study
Cockett, A. T. �., Barry, M. J., Holtgrewe, H. L., Sihelnik, S. A., Williams, R., & McConnell, J. D. (1992) · Cancer · Cited by 30
Self-citation
Cited by
Epidemiology of Prostate Cancer
Rawla, P. (2019) · World Journal of Oncology · doi:10.14740/wjon1191 · Cited by 2,776
Effect of Dutasteride on the Risk of Prostate Cancer
Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908127 · Cited by 1,152
Self-citationGratzke, C., Bachmann, A., Descazeaud, A., Drake, M. J., Madersbacher, S., Mamoulakis, C., Oelke, M., Tikkinen, K. A. O., & Gravas, S. (2015) · European Urology · doi:10.1016/j.eururo.2014.12.038 · Cited by 1,010
Roehrborn, C. G., Siami, P., Barkin, J., Damião, R., Major-Walker, K., Nandy, I., Morrill, B. B., Gagnier, R. P., & Montorsi, F. (2010) · European Urology · doi:10.1016/j.eururo.2009.09.035 · Cited by 788
Self-citationRoehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Self-citation
Metadata
- Authors
- McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., Lepor, H., McVary, K. T., Nyberg, L. M., Clarke, H. S., Crawford, E. D., Diokno, A., Foley, J. P., Foster, H. E., Jacobs, S. C., Kaplan, S. A., Kreder, K. J., Lieber, M. M., Lucia, M. S., Miller, G. J., Menon, M., Milam, D. F., Ramsdell, J. W., Schenkman, N. S., Slawin, K. M., & Smith, J. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-18
- Volume
- 349
- Issue
- 25
- Pages
- 2387-2398
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2121759271
- Cited by
- 2,043
- References
- 30
- FWCI
- 106.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.